Company intelligence / Profile preview
ToolGen
Seoul, Seoul, South Koreatoolgen.com ↗
- Ownership
- Private
- Employees
- ~80
- Development stage
- Other
01
Overview
ToolGen is a leading South Korean biotech company developing CRISPR, ZFN, and TALEN gene editing technologies, with an extensive IP portfolio, broad application in biomedicine and agriculture, and active licensing of core patents; current clinical results are predominantly pre-clinical, with research publications cited in areas such as Charcot-Marie-Tooth disease and experimental CAR-T approaches
- Therapeutic areas
- OtherRare Diseases
- Modalities
- CRISPR-based therapyGene therapyGenome editing technology
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Life Technologies (now Thermo Fisher Scientific)Thermo Fisher ScientificBayer (Monsanto, for agriculture IP licensing)KeyGene
Beyond the preview
Go deeper on ToolGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ToolGen.